𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer

✍ Scribed by Andrea Manni; Alice E. Boucher; Laurence M. Demers; Harold A. Harvey; Allan Lipton; Mary A. Simmonds; Mary Bartholomew

Publisher
Springer US
Year
1989
Tongue
English
Weight
752 KB
Volume
14
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined endocrine effects of LHRH agoni
Combined endocrine effects of LHRH agonist (Zoladex®) and tamoxifen (Nolvadex®) therapy in premenopausal women with breast cancer
✍ Mr J. F. R. Robertson; K. J. Walker; R. I. Nicholson; R. W. Blamey 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 2 views

Abstract In premenopausal women with breast cancer, the use of the luteinizing hormone releasing hormone agonist, goserelin, results in the production of serum levels of oestradiol equivalent to those after surgical oöphorectomy or in postmenopausal women. The standard first line hormonal treatment

Pharmacokinetic, biochemical and clinica
Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide–bischloroethylnitrosourea combination therapy in patients with advanced breast cancer
✍ Mark Clemons; Malcolm Ranson; Jennifer M. Margison; Hassan El Teraifi; Audrey Gr 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 107 KB

## Abstract We assessed whether split dosing with the methylating agent DTIC is an effective strategy for inactivating the DNA repair protein __O__6‐alkylguanine DNA‐ATase in order to decrease tumour resistance to BCNU. ATase levels in PBMCs were used as a surrogate for tumour ATase depletion to de